Drug Approval | November 12, 2021
Sun Pharma to introduce molnupiravir in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Evidence also shows better immune response to virus among users of spray
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Glycopyrrolate injection can also be used in adults as an adjunctive therapy for the treatment of gastrointestinal ulcer when a rapid effect is desired or when oral medication is not tolerated
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
A Sanofi R&D executive will join the Gyroscope Clinical Advisory Board to advise on matters related to the development of GT005 for geographic atrophy (GA).
The Lucent 3D Lumbar Interbody System features a functionally unique multi-component device manufactured in a 3D printing sequence
The company has operations in North America, Asia, and Europe,
Subscribe To Our Newsletter & Stay Updated
